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Background: More effective methods are needed to implement evidence-based findings into practice. The
Advancing Recovery Framework offers a multi-level approach to evidence-based practice implementation by
aligning purchasing and regulatory policies at the payer level with organizational change strategies at the
organizational level.
Methods: The Advancing Recovery Buprenorphine Implementation Study is a cluster-randomized controlled trial
designed to increase use of the evidence-based practice buprenorphine medication to treat opiate addiction. Ohio
Alcohol, Drug Addiction, and Mental Health Services Boards (ADAMHS), who are payers, and their addiction
treatment organizations were recruited for a trial to assess the effects of payer and treatment organization changes
(using the Advancing Recovery Framework) versus treatment organization changes alone on the use of
buprenorphine. A matched-pair randomization, based on county characteristics, was applied, resulting in seven
county ADAMHS boards and twenty-five treatment organizations in each arm. Opioid dependent patients are
nested within cluster (treatment organization), and treatment organization clusters are nested within ADAMHS
county board. The primary outcome is the percentage of individuals with an opioid dependence diagnosis who
use buprenorphine during the 24-month intervention period and the 12-month sustainability period. The trial is
currently in the baseline data collection stage.
Discussion: Although addiction treatment providers are under increasing pressure to implement evidence-based
practices that have been proven to improve patient outcomes, adoption of these practices lags, compared to other
areas of healthcare. Reasons frequently cited for the slow adoption of EBPs in addiction treatment include,
regulatory issues, staff, or client resistance and lack of resources. Yet the way addiction treatment is funded, the
payer’s role—has not received a lot of attention in research on EBP adoption.
This research is unique because it investigates the role of payers in evidence-based practice implementation using
a randomized controlled design instead of case examples. The testing of the Advancing Recovery Framework is
designed to broaden the understanding of the impact payers have on evidence-based practice (EBP) adoption.
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The use of evidence-based clinical practices in health
care is suboptimal [1,2]. The addiction treatment field
adopts evidence-based practices (EBPs) at an even lower
rate than general health care [3-5]. For example, use of
medication-assisted therapy for addiction disorders is
not standard practice, despite the evidence that medica-
tion improves clinical, societal and financial outcomes
through increased abstinence rates [6], reduced relapse
rates [7], and reduced criminal costs [8]. A survey of 354
private addiction treatment centers reported that 34 per-
cent of programs provided medication for opioid de-
pendence and 24% used medication for treatment of
alcohol dependence [9]. Within treatment programs that
do offer medication, only 40% of the treatment plans for
opioid dependence included medication [10].
Buprenorphine received Food and Drug Administra-
tion approval for treating opioid dependence in 2002 but
remains underutilized. Less than one-fifth of patients
with an opioid dependence diagnosis are offered
buprenorphine [11,12]. Its adoption has been impeded
by behavioral resistance, lack of or low reimbursement,
insufficient access to personnel needed to prescribe the
medication, licensure and contractual rules that prohibit
the use of any pharmacotherapies in some settings, and
insufficient organizational systems to encourage its use.
Buprenorphine was selected as a candidate for EBP im-
plementation and dissemination research because the
broad set of behavioral and systemic barriers that limit
its use incorporates factors that affect other EBPs with
poor use rates.
Payer policy and organizational interventions can ad-
dress barriers to the adoption of medication (and
evidence-based practices more generally) [13,14]. Policy
makers and local organizations collaborate to dissemin-
ate school reform, alternative energy use, and third-
world agricultural practices [15,16]. Few trials in
healthcare have tested the impact of aligning payer pol-
icy and treatment organization interventions to enhance
implementation of treatment innovations [17]. However,
from 2006 through 2010, NIATx (formerly the Network
for the Improvement of Addiction Treatment), a process
improvement research center based at the University of
Wisconsin–Madison, conducted a demonstration project
titled ‘Advancing Recovery: State and Treatment
Organization Partnerships for Quality Addiction Care’.
Funded by the Robert Wood Johnson Foundation, Ad-
vancing Recovery promoted the use of evidence-based
practices such as medication-assisted treatment by
building relationships between treatment organizations
and the payers that fund their services. These partner-
ships made system changes to regulatory, clinical and
administrative practices to increase the implementation
of EBPs [18]. Advancing Recovery involved payer-treatment organization partnerships in 12 states, but was
not a randomized controlled trial. The Advancing Re-
covery demonstration project did develop a framework
for systems change to be tested in this randomized trial,
calling it the Advancing Recovery Framework.
Objectives
The primary research question is to determine if the Ad-
vancing Recovery Framework increases the use of
buprenorphine in addiction treatment organizations.
The secondary research question is to determine if
county characteristics (e.g., percentage of opioid abusers,
existing addiction treatment medication availability, and
payment policy) and organizational characteristics (e.g.,
organization size, access to physicians, number of
nurses, percentage of clinicians with graduate degrees,
and patient demographic characteristics) can moderate
the delivery of buprenorphine.
Methods
Trial design
The participating ADAMHS boards have been random-
ized into two study conditions. In the Control Arm
(Arm 1), participants will use the NIATx model for
organizational change only. In Arm 2, participants will
use the Advancing Recovery Framework that includes
the payer intervention and NIATx models. Payers will
not play a direct role in the control arm. The NIATx
organizational change model (Figure 1) was chosen as
the control condition because research exists that
suggests organizational change models alone may be suf-
ficient for EBP implementation [19,20]. A cluster ran-
domized controlled design was used to study the effects
that payers (or county ADAMHS boards) and treatment
organizations have on buprenorphine adoption and also
to control for ‘contamination’ across the treatment and
control arms. A 1:1 allocation ratio of counties was uti-
lized in the randomization.
Participants
Ohio Alcohol, Drug Addiction and Mental Health
Boards (ADAMHS) coordinate the public behavioral
health system in Ohio. Each board covers one to five of
Ohio’s 88 total counties and disperses Substance Abuse
and Prevention Treatment (SAPT) block grant funds, as
well as funds from local levies directed to addiction ser-
vices. These Boards are responsible for 55% of addiction
treatment services funding and often have responsibility
for the quality and cost effectiveness of addiction treat-
ment services within their jurisdictions [21]. The boards
contract with provider organizations to deliver addiction
and mental health treatment services. All 46 of Ohio’s
ADAMHS boards were eligible for the study. The










Figure 1 The NIATx organizational change model.
Figure 2 Consort Diagram (Enrollment & Intervention Phases).
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Authorities from May to September, 2012. The study
team also actively recruited ADAMHS boards needed to
meet the study’s matching criteria. A total of 14 boards
representing 23 counties agreed to participate (Figure 2).
Within each board jurisdiction, treatment agencies with
75 or more annual admission were invited to participate
in the study. Fifty treatment agencies volunteered. Two
to eight treatment agencies are participating per board.Interventions
The Advancing Recovery Framework builds upon the multi-
organizational learning collaborative method used in the
NIATx 200 national trial to implement process improve-
ment strategies in over 200 treatment organizations [22,23].
The Advancing Recovery Framework delivers technical as-
sistance through learning sessions and coaching. Learning
sessions are face-to-face meetings that occur once in the
NIATx-only arm and three times in the Advancing Recovery
arm to facilitate partnering between the ADAMHS boards
and their treatment organizations. In these sessions, change
teams from the ADAMHS board area (Arm 2 only) and
each of the treatment organizations convene in face-to-face
meetings to support and encourage each other. Outside ex-
perts offer advice on changes to make and ways to makethem. Coaching assigns an expert in medication-assisted
treatment adoption and process improvement to help the
ADAMHS board and its treatment organizations make, sus-
tain and spread buprenorphine adoption efforts. Coaches
help the ADAMHS boards’ counties in Arm 2, and organi-
zations in both arms think through key issues, broker
relationships with other organizations, offer process im-
provement training, and suggest changes to make and how
to do so. Participants in both arms receive coaching through
monthly group teleconference calls, through e-mail, and at
in-person learning sessions.
The payer intervention portion of the Advancing
Recovery Framework has four phases: ‘Pre-Work for
Leadership’ identifies the individuals who will lead and
execute the change project; ‘Preparing the Change Leader
& Team’ provides training in change management
techniques; ‘Planning’ uses a five-lever policy analysis to
catalog barriers to buprenorphine use and pilot tests
potential tactics to remedy; and ‘Implementation’ takes
tactics to apply from the planning phase, implements
them, and focuses on sustaining the gains. During the
learning sessions and monthly coach calls between the
payer and treatment organizations, the payer has the
opportunity to partner and collaborate with treatment or-
ganizations. Table 1 outlines the steps, tools, and training
methods for each phase of the payer intervention model.
Table 1 Payer intervention model of the advancing recovery framework (applied in Arm 2 only)
Phase1 Steps Tools Training method(s)
Pre-work for Leadership To be completed as part of Executive Briefing by the




Coach call to Executive Sponsor to
review primer for Executive
Sponsor
1. Identify an Executive Sponsor for payer portion of
the project
Change leader training on how to
apply and interpret the 5 Levers
Barriers Assessment
2. Develop the strategic aim for buprenorphine
adoption.
3. Select change leader and team members who are
committed and make sure they have adequate time
to participate in the project.
Preparing the Change
Leader & Team
4. Change Leader & Team Training on organizational
and policy change techniques.
NIATx Workbook (Change
Leader Training Guide –
Administrative Version)
Provided in Learning Session 1





5. Conduct the 5 Levers Barriers Assessment.
(Customer Impact, Financial & Purchasing, Regulatory
& Policy, Operational, & Inter-organizational) to
identify list of potential barriers to remove
5-Levers Policy-Barriers
Assessment
Provided in Learning Session 1
and reinforced by coaches
throughout
6. Develop tactics to apply Implementation charter
form
7. Pilot test tactics




Change leader training in Learning
Sessions on the implementation
and sustainability process
9. Assign a process owner, and timeline with
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a mechanism for payers to identify systemic barriers to
EBP use and promote change. The ‘customer impact
analysis’ examines how the EBP benefits the customer,
affects the number or type (i.e., demographic) of cus-
tomers involved in treatment, and which customers are
needed to advocate for the change. A ‘financing and pur-
chasing analysis’ determines how financing, reimburse-
ment and payment provide incentives for EBP use. The
‘regulatory and policy analysis’ uncovers regulatory bar-
riers. The ‘operations analysis’ assesses the training and
skill-building payers and treatment organizations need
for EBP implementation. Finally, an ‘inter-organizational
analysis’ identifies what other organizations need to be
involved to remove regulatory or financing barriers.
Timeline
During project months 1 to 5, the study team will iden-
tify and recruit counties (through the Ohio Association
of County Behavioral Health Authorities) and treatment
organizations. In months 6 to 11, the study team will
collect baseline data on buprenorphine use rates, con-
duct buprenorphine training workshops for treatment
organizations, and update NIATx training materials toreflect the study conditions. In months 12 to 36, the
study team will implement the study arm interventions
and collect outcome data. During months 37 to 50, the
study team will collect quantitative data on the sustain-
ability of the changes. Data analysis, publication develop-
ment, and dissemination of findings will occur at several
points, but primarily during months 51 to 60.
Sample size
To determine sample size, we fit a linear mixed-effects
model to the monthly results for the performance meas-
ure of percent opioid dependent patients receiving
buprenorphine from each of the participating organiza-
tions and estimate the ‘payer-treatment organization’
effect. A mixed-effect model was selected instead of con-
ventional regression models because, first, the mean out-
comes for a given treatment organization are expected
to be correlated from month to month. A mixed-effect
model allows for auto-correlated error terms. Second, a
number of unobservable treatment organization charac-
teristics are likely to influence the key measures. Ran-
dom effects at the treatment organization level can be
employed within the mixed-effect model to capture the
correlation introduced by such characteristics. Proper
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for more reliable estimates of the fixed effects, starting
in months 6 to 11 (for baseline), then during months 12
to 36 (intervention stage), and through months 37 to 50
(follow-up stage). The power of the study design is de-
termined by the anticipated standardized effect size
based on effects experienced in the Advancing Recovery
pilot project. The Advancing Recovery pilot data found
that the payer-treatment organization intervention in-
creased buprenorphine use rates from 6% to 43%, with
an estimated standard deviation of 23.5% based on a
sample size of 1,016. This yields an effect size of 0.935.
Intraclass correlation (ICC) among counties affects the
power of cluster-randomized trials [24]. An estimate of
ICC is around 0.05. For this study, a dropout rate of 20%
is being proposed, giving a total of 40 organizations
available for analysis. With a total of 40 treatment orga-
nizations, each with an average of 91 patients, the study
will achieve at least a power of 0.82 with a one-tailed
type I error rate of 0.05. Power and sample size calcula-
tions were performed using Optimal Design Software by
Raudenbush (Version 3.01) [25].
Randomization & implementation
Matched-pair blocks were created on the basis of the
county characteristics of: percentage of opiate admissions;
population covered; and ratio of opiate addiction treat-
ment admissions to physicians licensed to prescribe
buprenorphine [26]. The cut-off criteria used for matching,
based on the median measures from the 2011 Ohio Depart-
ment of Alcohol and Drug Addiction Services treatment
organization dataset, were: 20% opiate admissions (above/
below); 200,00 people covered (above/below); and 50 treat-
ment admissions per physicians in the county registered to
prescribe buprenorphine per annum (above/below). As a
result, seven county board matched-pairs were identified. A
random number generator was utilized within the seven
county board pairs to assign organizations into one of the
two study conditions. Study staff completed enrollment and
received consent approval from the county boards as well
as providers. No visible concealment was applied, and
blinding of participants and researchers was considered in-
feasible due to logistical reasons.
Data analysis
Because the number of treatment organizations within an
ADAMHS Board is small (n = 2 to 8) we intend to use an
optimal design in which treatment arms are allocated
following a multi-site cluster randomization procedure
[27,28]. The initial exploratory analyses of both outcomes
and covariates will assess standard summary statistics and
graphical presentations. Scatter plots and correlation ana-
lyses identify possible associations between outcome and
predictor variables. The analysis will represent the multi-site cluster randomized trial as a mixed-effects model; per-
centage of buprenorphine use by opioid dependent patients
is nested within cluster (treatment organization); and clus-
ters are nested within site (ADAMHS board). In this
mixed-effects model, there will be random effects due to
county board and organization; fixed effect due to study
arm and time. For the percent of opioid admissions receiv-
ing buprenorphine, a logistic regression analysis will be
performed. We will examine the Advancing Recovery effect
using a separate model at each time point and in an omni-
bus growth curve model that includes the main effects of
Advancing Recovery and Time as well as the interaction
between Advancing Recovery and Time. The percent of
opioid patients receiving buprenorphine will be measured
monthly for each organization, and it is expected that these
values will be correlated over time. Therefore, instead of as-
suming an independence (i.e., zero correlation) or a com-
pound symmetry covariance structure (i.e., a constant
correlation regardless of the proximity of measurement
time points), we will allow errors to be first-order auto-
correlated, denoted as AR (1). This can be done by allowing
an additional parameter in the mixed-effects model that
represents the correlation between the two most adjacent
measures of Opioid Patients Receiving Buprenorphine. This
correlation is reduced exponentially as the measures be-
come further apart.
For the ADAMHS board and organizational covariates,
at each time point we will assess moderation by including
each potential moderator as an independent variable and as
an interaction with the Advancing Recovery effect. Statis-
tical significance of the interaction effect will indicate the
presence of moderation. The estimate for the effect size of
moderation, which is cross-level interaction, is between
0.17 and 0.19.
Ethics
The study received approval from the institutional review
boards at the University of Wisconsin–Madison, Ohio
Department of Health’s Human Subjects Institutional
Review Board, and Oregon Health and Science University.
Trial status
The recruitment phase of the trial has just been com-
pleted and baseline data collection has begun.
Discussion
Conceptual multi-level models of EBP adoption are present
in the literature and are based on correlates of EBP
adoption discovered at the larger systems/environment,
organizational, and individual levels [13,17,29]. These
models identify which factors EBP implementation efforts
should attempt to influence at the different levels in the
healthcare system, but do not address how to change these
factors. Accordingly, this research represents a movement
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ing. This progression is described in McGovern’s ‘Imple-
mentation Research Flow’ paradigm, which explains how
the purpose of implementation models is to positively influ-
ence the implementation and maintenance trajectories of
the EBP adoption [30].
At present, the implementation research on how adminis-
trative practices at the payer level promote use of clinical
practices at the treatment organization level primarily relies
on case examples. The described research protocol has the
unique aspect of randomizing by payer. The use of imple-
mentation research randomizing by county has been limited
[31,32], and no instances of randomization at the state level
were found. Research studying use of payer administrative
practices to promote clinical evidence-based practice imple-
mentation should begin to use randomized trials to aug-
ment and validate findings found in payer case-examples.
This trial is taking lessons from past implementation
research through case examples from the Advancing
Recovery pilot [33-39], and packages them into an im-
plementation model [18]. The research trial testing the
Advancing Recovery Framework will build on several
implementation research questions: What are the roles
of payers with planning and stakeholder engagement in
the provision of EBPs? What policy levers have an im-
pact on EBP implementation and sustainability rate?
What are the synergistic effects of having multiple levels
focused on implementing a targeted EBP? What is the
role of leadership at the payer and provider levels in the
broader use of EBPs? What training and technical assist-
ance offerings in the learning collaborative model are
most helpful in a multi-level design?
Ohio was selected as a research site because it was con-
sidered to be a representative governmental healthcare en-
vironment to test this implementation model. A total of
34% of the states in the United States have county or re-
gion boards to distribute SAPT block grant funds. Each
Ohio ADAMHS board represents a unique payer environ-
ment. The state has a mix of urban and rural counties.
Within these counties, buprenorphine use varies from 7%
to 58%. Limitations could be present due to the research
environment. This trial addresses governmental payers se-
curing healthcare services. Governmental healthcare is a
considerable enterprise, where an effective framework for
evidence-based practice implementation could prove to
be extremely helpful. While this trial may not be
generalizable to governmental payers for other commu-
nity services, the Advancing Recovery framework could
give these sectors interventions to consider in their efforts
to improve services.
Conclusion
In conclusion, this trial will contribute to the evolving im-
plementation science field over the next five years. Futureresults of this multi-level approach will be published as they
become available.
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